The 2019 Novel Coronavirus Disease in Pregnancy: A Systematic Review

Makvandi, Somayeh; Mahdavian, Mitra; Kazemi-Nia, Goli; Vahedian‐Azimi, Amir; Guest, Paul C.; Karimi, Leila; Sahebkar, Amirhossein

doi:10.1007/978-3-030-59261-5_27

Cited by 14 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the COVID-19 pandemic, the number of SARS-CoV-2infected pregnant women has been increasing worldwide. There are several reports showing higher levels of inflammatory biomarkers such as CRP in pregnant women with COVID-19 [104][105][106], suggesting MIA in pregnant women with COVID-19. Considering the risk for maternal infection on neuropsychiatric disorders in offspring, offspring follow-up after maternal infection by SARS-CoV-2 is important (Fig.…”

Section: Other Mechanismsmentioning

confidence: 99%

Mechanisms of action of fluvoxamine for COVID-19: a historical review

2022

View full text Add to dashboard Cite

The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of prophylactic and therapeutic drugs for persons infected with the virus. Drug repurposing for the COVID-19 pandemic has received particular attention. Increasing clinical data suggest that antidepressant use in early-stage subjects with COVID-19 might be associated with a reduced risk of intubation or death. Among the antidepressants, fluvoxamine is the most attractive drug for mild to moderate subjects with COVID-19. In this article, we review the mechanisms of action (i.e., serotonin transporter, sigma-1 receptor, and acid sphingomyelinase) of fluvoxamine for COVID-19. Furthermore, we discuss a possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders (i.e., autism spectrum disorder and schizophrenia) in offspring.

show abstract

Section: Other Mechanismsmentioning

confidence: 99%

Mechanisms of action of fluvoxamine for COVID-19: a historical review

2022

View full text Add to dashboard Cite

show abstract

“…Overall, ICU admission occurred within one week after SARS-CoV-2 diagnosis (range, 0 to 3 weeks). Median ICU length of stay was 9 days (IQR, [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. Differences between forms of respiratory support regarding patient characteristics and treatment modalities are shown in Table 3.…”

Section: Icu Treatment-respiratory Treatmentmentioning

confidence: 99%

“…In this cohort of patients, fifteen (n = 22 (68%)) women recovered from COVID-19 before childbirth. Median time from infection to childbirth was 8 weeks (IQR, [4][5][6][7][8][9][10][11][12][13][14]. This resulted in a statistically significant pregnancy prolongation in comparison to the other treatments (p < 0.00034).…”

Section: Icu Treatment-respiratory Treatmentmentioning

confidence: 99%

Pregnant and Postpartum Women Requiring Intensive Care Treatment for COVID-19—First Data from the CRONOS-Registry

Sitter

Pecks

Rüdiger

et al. 2022

JCM

View full text Add to dashboard Cite

(1) Background: Data on coronavirus 2 infection during pregnancy vary. We aimed to describe maternal characteristics and clinical presentation of SARS-CoV-2 positive women requiring intensive care treatment for COVID-19 during pregnancy and postpartum period based on data of a comprehensive German surveillance system in obstetric patients. (2) Methods: Data from COVID-19 Related Obstetric and Neonatal Outcome Study (CRONOS), a prospective multicenter registry for SARS-CoV-2 positive pregnant women, was analyzed with respect to ICU treatment. All women requiring intensive care treatment for COVID-19 were included and compared regarding maternal characteristics, course of disease, as well as maternal and neonatal outcomes. (3) Results: Of 2650 cases in CRONOS, 101 women (4%) had a documented ICU stay. Median maternal age was 33 (IQR, 30–36) years. COVID-19 was diagnosed at a median gestational age of 33 (IQR, 28–35) weeks. As the most invasive form of COVID-19 treatment interventions, patients received either continuous monitoring of vital signs without further treatment requirement (n = 6), insufflation of oxygen (n = 30), non-invasive ventilation (n = 22), invasive ventilation (n = 28), or escalation to extracorporeal membrane oxygenation (n = 15). No significant clinical differences were identified between patients receiving different forms of ventilatory support for COVID-19. Prevalence of preterm delivery was significantly higher in women receiving invasive respiratory treatments. Four women died of COVID-19 and six fetuses were stillborn. (4) Conclusions: Our cohort shows that progression of COVID-19 is rare in pregnant and postpartum women treated in the ICU. Preterm birth rate is high and COVID-19 requiring respiratory support increases the risk of poor maternal and neonatal outcome.

show abstract

“…Since the COVID-19 epidemic, several studies have reported that the clinical symptoms and laboratory findings of patients with combined SARS-CoV-2 infection in pregnancy are consistent with those of the general population, with patients showing increased C-reactive protein (CRP) and decreased lymphocytes in their hemogram [ 12 ]. Tanacan et al found that pregnant women with COVID-19 had significantly increased pregnancy complications and inflammatory markers [ 13 ].…”

Section: Mechanismsmentioning

confidence: 99%

Deleterious effects of nervous system in the offspring following maternal SARS-CoV-2 infection during the COVID-19 pandemic

Wang

Huang

et al. 2022

Transl Psychiatry

View full text Add to dashboard Cite

During the Coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is universally susceptible to all types of populations. In addition to the elderly and children becoming the groups of great concern, pregnant women carrying new lives need to be even more alert to SARS-CoV-2 infection. Studies have shown that pregnant women infected with SARS-CoV-2 can lead to brain damage and post-birth psychiatric disorders in offspring. It has been widely recognized that SARS-CoV-2 can affect the development of the fetal nervous system directly or indirectly. Pregnant women are recommended to mitigate the effects of COVID-19 on the fetus through vaccination, nutritional supplements, and psychological support. This review summarizes the possible mechanisms of the nervous system effects of SARS-CoV-2 infection on their offspring during the pregnancy and analyzes the available prophylactic and treatment strategies to improve the prognosis of fetal-related neuropsychiatric diseases after birth.

show abstract

The 2019 Novel Coronavirus Disease in Pregnancy: A Systematic Review

Cited by 14 publications

References 23 publications

Mechanisms of action of fluvoxamine for COVID-19: a historical review

Mechanisms of action of fluvoxamine for COVID-19: a historical review

Pregnant and Postpartum Women Requiring Intensive Care Treatment for COVID-19—First Data from the CRONOS-Registry

Deleterious effects of nervous system in the offspring following maternal SARS-CoV-2 infection during the COVID-19 pandemic

Contact Info

Product

Resources

About